IG7 Stock Overview
Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.004 |
| 52 Week High | AU$0.012 |
| 52 Week Low | AU$0.0005 |
| Beta | 0.95 |
| 11 Month Change | -27.27% |
| 3 Month Change | 300.00% |
| 1 Year Change | 14.29% |
| 33 Year Change | -89.19% |
| 5 Year Change | -92.31% |
| Change since IPO | -60.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IG7 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -11.1% | -4.4% | -1.9% |
| 1Y | 14.3% | -1.0% | 12.3% |
Return vs Industry: IG7 exceeded the German Life Sciences industry which returned -1% over the past year.
Return vs Market: IG7 exceeded the German Market which returned 12.3% over the past year.
Price Volatility
| IG7 volatility | |
|---|---|
| IG7 Average Weekly Movement | 74.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IG7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IG7's weekly volatility has decreased from 90% to 74% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company’s product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port.
Memphasys Limited Fundamentals Summary
| IG7 fundamental statistics | |
|---|---|
| Market cap | €6.27m |
| Earnings (TTM) | -€2.75m |
| Revenue (TTM) | €675.21k |
9.3x
P/S Ratio-2.3x
P/E RatioIs IG7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IG7 income statement (TTM) | |
|---|---|
| Revenue | AU$1.09m |
| Cost of Revenue | AU$115.46k |
| Gross Profit | AU$974.38k |
| Other Expenses | AU$5.42m |
| Earnings | -AU$4.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 89.41% |
| Net Profit Margin | -407.58% |
| Debt/Equity Ratio | 64.5% |
How did IG7 perform over the long term?
See historical performance and comparison